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Background: Hypersensitivity pneumonitis (HP), an immune-mediated inﬂammatory interstitial lung
disease (ILD), can result from exposure to several well-recognized antigens. Despite antigen avoidance,
progressive pulmonary ﬁbrosis and death can occur, suggesting that additional factors may contribute to
disease activity. We hypothesized that the presence of autoimmunity might impact clinical course in
patients with HP. In this study, we examined an HP cohort to identify those with HP and autoimmune
features (HPAF), and determine its prevalence and outcomes.
Methods: The University of Chicago ILD registry was screened to identify patients with HP. Patients were
characterized as HPAF if they had an autoimmune disease or features of autoimmunity, deﬁned as the
presence of speciﬁc connective tissue disease (CTD) symptoms and serologies. Demographics, clinical
characteristics, and outcomes were compared between groups. Survival analysis was performed using
Cox regression to identify predictors of transplant-free survival in this cohort.
Results: One hundred twenty patients with chronic, ﬁbrotic HP were identiﬁed. Of these, 18/120 (15%)
were characterized as HPAF. Compared to those without evidence of autoimmunity, patients with HPAF
had a higher proportion of females (54% vs. 83%, respectively; p ¼ 0.02) but were otherwise similar with
regard to clinical characteristics. The presence of autoimmunity was an independent predictor of
increased mortality (HR 4.45; 95% CI 1.43e13.88; p ¼ 0.01) after multivariable adjustment.
Conclusions: Fifteen percent of patients with chronic, ﬁbrotic HP displayed evidence of a concurrent
deﬁned autoimmune disease or autoimmune features suggestive of CTD. The presence of autoimmunity
in patients with chronic, ﬁbrotic HP may portend a poorer prognosis. Future studies are needed to
validate these ﬁndings and determine the impact of immunosuppressive treatment.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Interstitial lung disease (ILD) encompasses a heterogeneous
group of diffuse parenchymal lung diseases often characterized by
inﬂammation and scarring of the pulmonary parenchyma, resulting
in signiﬁcant morbidity and mortality [1]. While it is well-
recognized that ILD can develop secondary to connective tissue
disease (CTD), there is increasing awareness that features of auto-
immunity are common among patients characterized as having, Section of Pulmonary and
icago, IL 60637, USA.
).
Critical Care and Sleep Med-
reet, Suite 3400, Sacramento,
Ltd. This is an open access article uidiopathic interstitial pneumonia (IIP) [2], and that systematic
evaluation of patients with IIP can reveal a previously unrecognized
autoimmune process [3e6] The clinical implications of autoim-
mune features in those with IIP who fail to meet established
rheumatologic criteria remain unclear, but some studies suggest an
improved prognosis [7,8].
Hypersensitivity pneumonitis (HP) is an ILD caused by a wide
variety of small organic particles. These antigens include fungi,
proteins from animals and insects and some chemical compounds
[9]. As these antigens are ubiquitous, it remains unclear why only a
small fraction of exposed individuals develop HP. One explanation
may lie with abnormal T cell function, as individuals with HP do not
suppress T-cell proliferation after exposure to known antigenwhen
compared to healthy controls [10]. T cell dysregulation is alsonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviation list
aCCP anti-citrullinated protein antibody
ANA antinuclear antibody
ANCA antineutrophil cytoplasmic antibody
BMI body mass index
CAD coronary artery disease
CI Conﬁdence Interval
C-reactive protein CRP
CTD connective tissue disease
DLCO diffusion capacity of the lung for carbon monoxide
FVC forced vital capacity
GER gastroesophageal reﬂux
HLA human leukocyte antigen
HP Hypersensitivity pneumonitis
HR hazard ratio
HRCT high-resolution computed tomagraphy
IIP idiopathic interstitial pneumonia
ILD interstitial lung disease
IPF idiopathic pulmonary ﬁbrosis
IRB institutional review board
OR odds ratio




SLB surgical lung biopsy
SLE systemic lupus erythematosus
TLC total lung capacity
UCTD undifferentiated connective tissue disease
UIP usual interstitial pneumonia
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the question of whether autoimmune disease is more likely to be
present among patients with HP.
In this study, we systematically assessed an HP cohort to identify
patients with autoimmune features (HPAF), deﬁned as the presence
of documented autoimmune disease or contemporaneous auto-
immune serologies and clinical features suggestive of an undiffer-
entiated connective tissue disease (UCTD) [7]. We then
characterized clinical features and outcomes among patients with
HPAF and compared them to those HP patients without evidence of
autoimmunity.
1. Materials and methods
1.1. Study population
This retrospective analysis was conducted at the University of
Chicago with approval of our Institutional Review Board (IRB
#14163A) and all patients provided informed consent. We identi-
ﬁed consecutive patients aged 18 years who enrolled in the
University of Chicago ILD registry, were diagnosed with HP based
on multidisciplinary evaluation, and were seen in the ILD clinic
between January 1, 2006 and February 28, 2015. (Fig. 1). Data was
extracted using the electronic medical record. Variables collected
included demographic data (age, race/ethnicity, gender), symp-
toms, co-morbid conditions (autoimmune disease, coronary artery
disease, gastroesophageal reﬂux), history of tobacco use, use of
chronic corticosteroid and immunosuppressive therapy, physical
examination ﬁndings such as body mass index (BMI), crackles and
clubbing, assessment of environmental antigen exposures (avian,
mold, hot tub, unknown), laboratory data including serologies and
C-reactive protein (CRP), serial PFTs including percent predicted
total lung capacity (TLC), forced vital capacity (FVC) and diffusion
capacity of the lung for carbon monoxide (DLCO), six minute walk
test and histopathologic ﬁndings. An experienced pulmonary
pathologist with expertise in ILD previously reviewed all surgical
lung biopsies. Outcomes assessed included all-causemortality, lung
transplantation and 10% decline in FVC. Outcomes were ascer-
tained by review of medical records, telephone interviews and the
Social Security Death Index.
1.2. Enrollment criteria
All patients in the University of Chicago ILD registry are assessed
for exposure to antigens commonly associated with HP, regardlessof referring diagnosis. A diagnosis of HP was based on multidisci-
plinary evaluation of patients' clinical features, HRCT ﬁndings and
surgical lung biopsy results by physicians with expertise in ILD.
Patients were diagnosed with HP and were included in the current
study if they met the following criteria:
(1) HRCT features compatible with HP: mosaic attenuation/air
trapping, centrilobular nodules, reticulation, traction bronchiec-
tasis, and honeycombing. (2) Surgical lung biopsy specimens, when
obtained, demonstrated presence of a histologic pattern consistent
with HP. This included lymphocytic predominant interstitial in-
ﬁltrates, with/without poorly formed granulomas, distributed in a
bronchiolocentric pattern. Histologic ﬁbrosis was also noted when
present. (3) Exclusion of an alternative etiology for these ﬁndings.
The presence of antibodies to serum precipitins supported the
diagnosis, but was not a requirement.
1.3. HRCT review and scoring
Features suggesting HP and pulmonary ﬁbrosis, as deﬁned by
reticulation, traction bronchiectasis or honeycombing pattern,
were recorded. All HRCTs were systematically reviewed and scored
by a senior chest radiologist (S.M.) who was blinded to clinical
phenotype. The mean extent of these morphological features was
scored to the nearest 5% in all three zones of each lung as previously
described [14,15] resulting in a semi-quantitative HRCT ﬁbrosis
score. These ﬁndings were graded on a scale of 1e4: 1 e normal
attenuation; 2 e reticular abnormality; 3 e traction bronchiectasis;
and 4 e honeycombing. Independent assessment was made for
each of these four HRCT ﬁndings in three (upper, middle and lower)
zones of each lung. The score for each zone was determined by
multiplying the grading scale score by the percentage involvement
for each zone. The average score of all six zones was calculated as
the total score for each patient. Using this method, the highest score
was 203 points and the lowest score was 100 points.
1.4. Autoimmune features
Patients were classiﬁed as HPAF if they had a documented
diagnosis of autoimmune disease [16e19] including scleroderma,
Sjogren's disease, idiopathic inﬂammatory myopathy (IIM), sys-
temic lupus erythematosus (SLE), rheumatoid arthritis (RA) and
ulcerative colitis. Patients were also classiﬁed as HPAF if at least one
speciﬁc CTD symptom and one serologic test suggestive of auto-
immune disease were present, as previously proposed by Corte
et al. [7]. Speciﬁc CTD symptoms included Raynaud's phenomenon,
Fig. 1. Consort diagram.
Table 1
Autoimmune disease or features in hypersensitivity pneumonitis.
Autoimmune disease or features n (%)
Autoimmune diseasea 9 (50.0)
Scleroderma 1 (5.6)
Sjogren's disease 2 (11.1)
Idiopathic inﬂammatory myopathy 1 (5.6)
Systemic lupus erythematosus 2 (11.1)
Rheumatoid arthritis 4 (22.2)
Ulcerative colitis 1 (5.6)
Autoimmune features 9 (50.0)
a Some patients had more than one autoimmune disease.
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and proximal muscle weakness. Positive autoimmune serologies
were an anti-nuclear antibody (ANA) 1:320, a rheumatoid factor
(RF)  3x upper limit of normal, or a positive anti-neutrophil
cytoplasmic antibody (ANCA), cyclic citrullinated peptide (aCCP);
Jo1; dsDNA; ribonucleoprotein (anti-RNP); Scl-70; SS-A/Ro or SS-B/
La. Patients were stratiﬁed based on HPAF status and further sub-
stratiﬁed based on the presence of deﬁned autoimmune disease.
1.5. Statistical analysis
Continuous variables were reported as means with standard
deviation (SD) and compared using a two-tailed student's t-test.
Categorical variables were reported as counts and percentages and
compared using the Chi-square test or Fisher's exact test, as
appropriate. A p-value of <0.05 was considered to be signiﬁcant.
Survival analysis was performed using univariate and multivariable
Cox proportional hazards analysis along with the unadjusted log
rank test and plotted using the Kaplan-Meier survival estimator.
Transplant-free survival was deﬁned as time from diagnosis to
death or lung transplantation. Patients who were lost to follow-up
were censored at that time. All data analysis was performed in Stata
version 13.1 (Stata Corp; College Station, Texas).
2. Results
Of 1045 patients enrolled in our ILD registry, 158 had an ICD-9
diagnosis code of HP (Fig. 1). Of these 158, 38 were excluded due
to an alternate ILD diagnosis or insufﬁcient data to verify their
diagnosis, leaving 120 patients with HP based on a multidisci-
plinary review of clinical data, radiographic and/or pathologic
ﬁndings and a compatible exposure history. All 120 patients had
chronic, ﬁbrotic HP based on HRCT and/or SLB. Eighteen patients
(15%) met criteria for HPAF. Of these patients, nine had a docu-
mented autoimmune disease (scleroderma, Sjogren's disease, IIM,
SLE, RA, ulcerative colitis) and nine displayed features of autoim-
munity (Table 1 and Supplemental Table 1).
Baseline demographics and clinical characteristics of the entirecohort revealed that mean age at diagnosis of HP was 63 years (±10
years); with a mean BMI of 32 (±8) and a Caucasian (83%) and fe-
male predominance (58%). Comorbid clinical conditions included
gastroesophageal reﬂux (59%) and coronary artery disease (21%).
Fifty-eight percent had a prior smoking history and 72% required
chronic systemic corticosteroid use for their ILD. On examination,
most had crackles (85%) while a minority of patients had digital
clubbing (24%). Exposure to avian antigens (47%) was the most
common environmental exposure identiﬁed.
When comparing baseline characteristics between HPAF and HP
patients without evidence of autoimmunity, HPAF had a higher
proportion of females (83% vs. 54%, respectively; p ¼ 0.02) and
demonstrated less digital clubbing (6% vs. 28% p ¼ 0.045) (Table 2).
There were no differences between groups with regard to other
demographic characteristics, antigen exposure, radiographic or
histopathologic features, or pulmonary function testing (Tables 2
and 3). When comparing autoimmune serologies and clinical fea-
tures between groups (Table 4), those meeting predeﬁned criteria
for HPAF had a higher prevalence of positive ANA, SS-A, anti-
dsDNA, digital arthralgias, morning stiffness and dry eyes and dry
mouth than patients with HP who did not meet these criteria.
During the study period, 28% of the entire HP cohort either died
or underwent lung transplantation (Table 5 and Supplemental
Fig. 1). Mean survival was 16.5 months (±13.0 months) in HPAF
compared to 29.7 months (±21.5 months) (p¼ 0.103) in HPwithout
Table 2
Baseline Characteristics in HP patients with and without autoimmune features.
Characteristics HPAF (n ¼ 18) HP without AF (n ¼ 102) p-value
Age, mean (±SD) 62.2 (9.5) 62.7 (10.5) 0.858
Female gender, n (%) 15 (83.3) 55 (53.9) 0.020
Race/ethnicity
Caucasian, n (%) 13 (72.2) 87 (85.3) 0.170
Hispanic, n (%) 1 (5.6) 9 (8.8) 1.000
African American, n (%) 2 (11.1) 5 (4.9) 0.282
Asian, n (%) 2 (11.1) 1 (0.98) 0.059
BMI, mean (±SD) 31.1 (8.2) 32.6 (8.0) 0.470
Ever smoker, n (%) 8 (44.4) 62 (60.8) 0.195
Chronic systemic corticosteroid use, n (%) 16 (61.5) 70 (74.5) 0.195
Other immunosuppressive therapy, n (%) 5 (27.8) 31 (30.4) 0.823
Antigen exposure
Avian, n (%) 8 (44.4) 48 (47.1) 0.838
Mold, n (%) 6 (33.3) 29 (28.4) 0.673
Hot tub, n (%) 0 (0) 3 (2.9) 0.611
Unknown, n (%) 4 (22.2) 34 (33.3) 0.350
Gastroesophageal reﬂux, n (%) 13 (72.2) 58 (56.9) 0.222
Coronary artery disease, n (%) 4 (22.2) 21 (20.6) 0.875
Crackles, n (%) 15 (83.3) 87 (85.3) 0.830
Clubbing, n (%) 1 (5.6) 28 (27.5) 0.045
HP¼Hypersensitivity Pneumonitis; HPAF¼HP with Autoimmune features as deﬁned in the text; AF ¼ Autoimmune features.
Table 3
Assessment of lung function, HRCT and pathologic characteristics in HP.
Characteristics HPAF (n ¼ 18) HP without AF (n ¼ 102) p-value
Pulmonary function tests
TLC' (% predicted) (±SD) 72.9 (16.0) 72.3 (18.4) 0.889
FVC@ (% predicted) (±SD) 63.7 (20.3) 65.1 (18.7) 0.773
DLCO (% predicted) (±SD) 55.1 (26.7) 54.3 (24.2) 0.906
Oxygen therapy, n (%) 7 (38.9) 61 (59.8) 0.099
6MWT distance (feet) (±SD) 1004.3 (424) 1120.0 (451) 0.328
HRCT features
HRCT ﬁbrosis score, mean (±SD) 123.3 (14.0) 124.0 (17.4) 0.862
Mosaic attenuation, n (%) 15 (83.3) 88 (86.3) 0.741
Centrilobular nodules, n (%) 11 (61.1) 40 (39.2) 0.083
Ground glass opacities, n (%) 17 (94.4) 97 (95.1) 0.631
Reticulation, n (%) 14 (77.8) 78 (76.5) 1.000
Traction bronchiectasis, n (%) 14 (77.8) 84 (82.4) 0.644
Honeycombing, n (%) 7 (38.9) 43 (42.2) 0.795
Absence of lower zone predominant ﬁbrosis, n (%) 10 (55.6) 59 (57.8) 0.856
Histopathologic features
Surgical lung biopsy obtained, n (%) 14 (77.8) 60 (58.8) 0.127
Poorly formed granulomas, n (%) 11 (78.6) 37 (61.7) 0.233
Lymphoplasmacytic inﬁltration/GC, n (%) 6 (42.9) 13 (21.7) 0.170
Honeycombing with UIP pattern, n (%) 7 (50.0) 28 (46.7) 0.822
HP¼Hypersensitivity Pneumonitis; HPAF¼Hypersensitivity Pneumonitis with Autoimmune features as deﬁned in the text; AF ¼ Autoimmune features; n ¼ 112; @n ¼ 114;
6MWT ¼ 6 min walk test, n ¼ 109; HRCT¼High-resolution computerized tomography scan; GC ¼ Germinal centers.
Table 4
Autoimmune serologic tests and clinical characteristics.
Characteristics HPAF (n ¼ 18) HP without AF (n ¼ 102) p-value
Autoimmune serologic tests
ANA  1:320, n (%) 11 (61.1) 23 (22.5) 0.001
RF  3x upper limit normal, n (%) 0 (0) 1 (1.0) 1.000
Anti-ENA RNP, n (%) 1 (5.5) 0 (0) 0.154
Anti-topoisomerase (Scl-70), n (%) 1 (5.5) 1 (1.0) 0.285
Anti-Ro (SS-A), n (%) 2 (11.1) 0 (0) 0.023
Anti-La (SSeB), n (%) 0 (0) 1 (1.0) 1.000
Anti-dsDNA, n (%) 3 (16.7) 1 (1.0) 0.011
Anti-CCP, n (%) 2 (11.1) 1 (1.0) 0.061
C-reactive protein', mean (±SD) 13.6 (26.2) 9.9 (25.6) 0.575
Autoimmune clinical features
Raynaud's phenomenon, n (%) 3 (16.7) 6 (5.9) 0.109
Arthralgias/multiple joint swelling, n (%) 6 (33.3) 3 (2.9) <0.001
Morning stiffness, n (%) 6 (33.3) 3 (2.9) <0.001
Dry mouth/dry eyes, n (%) 12 (66.7) 23 (22.5) <0.001
Proximal muscle weakness, n (%) 2 (11.1) 2 (2.0) 0.106
HP¼Hypersensitivity Pneumonitis; HPAF¼Hypersensitivity Pneumonitis with Autoimmune features as deﬁned in the text; AF ¼ Autoimmune features.
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Table 5
Outcomes in patients with HP.
Characteristics HPAF (n ¼ 18) HP without AF (n ¼ 102) p-value
Deceased, n (%) 5 (27.8) 24 (23.5) 0.698
Mean survival period, months (±SD) 16.5 (13.0) 29.7 (21.5) 0.103
Transplanted, n (%) 1 (5.6) 4 (3.9) 0.749
Mean Time to transplant, months (±SD) 23.6 (0) 33.2 (28.4) 0.528
10% FVC declinea, n (%) 6 (50) 24 (30.4) 0.178
Mean Time to 10% FVC decline, months (±SD) 26.2 (16) 18.2 (18.2) 0.337
HP¼Hypersensitivity Pneumonitis; HPAF¼Hypersensitivity Pneumonitis with Autoimmune features as deﬁned in the text; AF ¼ Autoimmune features.
a Follow up FVC available for 91 HP patients; 12 and 79, with and without autoimmune disease or features respectively.
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ferences between groups with regard to number of deaths (28% vs
24%, respectively; p ¼ 0.698) or lung transplantation (6% vs 4%,
respectively; p ¼ 0.75). The number of patients with a 10% or more
decline in percentage predicted FVC did not differ (50% in HPAF vs
30% in HPwithout autoimmune features; p¼ 0.178) and the time to
FVC decline was similar in both groups (26 ± 16 months vs 18 ± 18
months; p ¼ 0.337).
The unadjusted comparison of HPAF to HP subjects without
autoimmune features demonstrated no difference in survival be-
tween groups (p ¼ 0.59) (Fig. 2). HPAF was sub-stratiﬁed based on
the presence of deﬁned autoimmune disease and no survival dif-
ferencewas detected (p¼ 0.47). However, when stratiﬁcation of the
entire HP cohort was performed by race/ethnicity, survival was
greatest among non-Caucasian subjects (p ¼ 0.036) (Fig. 3). Strat-
iﬁcation of the entire HP cohort based on identiﬁcation of an
inciting antigen showed that antigen detection had no effect on
prognosis (data not shown).
Unadjusted predictors of transplant-free survival included
Caucasian race (HR 8.42; 95% CI 1.15e61.68; p ¼ 0.036), BMI (HR
0.95; 95% CI 0.90e0.99; p¼ 0.034), presence of digital clubbing (HR
3.47; 95% CI 1.77e6.81; p < 0.001), HRCT ﬁbrosis score (HR 1.04;
95% CI 1.02e1.05; p < 0.001) (Supplemental Fig. 2), and oxygenFig. 2. Survival among patients wittherapy (HR 4.38; 95% CI 1.81e10.59; p ¼ 0.001) (Table 6). After
adjustment for age, gender, race, BMI, digital clubbing, oxygen
therapy and disease severity (HRCT ﬁbrosis score and percentage
predicted FVC and DLCO), multivariable Cox regression analysis
demonstrated HPAF to be an independent factor predicting mor-
tality or lung transplantation (HR 4.45; 95% CI 1.43e13.88;
p¼ 0.01). Predictors of transplant-free survival in multivariable Cox
regression analysis also included non-Caucasian race (HR 9.33; 95%
CI 1.14e76.30; p ¼ 0.037) and HRCT ﬁbrosis score (HR 1.02; 95% CI
1.00e1.04; p ¼ 0.045).
3. Discussion
In this study, we showed that a signiﬁcant minority of patients
with HP displayed evidence of a concurrent deﬁned autoimmune
disease or autoimmune features suggestive of CTD. Patients with
HPAF were predominantly female. We found that the presence of
autoimmune disease or autoimmune features independently pre-
dicted worse outcomes for patients with HP after controlling for
disease severity and radiographic extent of ﬁbrosis. To our knowl-
edge, this is the ﬁrst study of autoimmunity in HP and identiﬁes
clinical factors associated with worse outcomes.
Predictors of survival in HP have previously been reported in theh HP stratiﬁed by HPAF status.
Fig. 3. Survival among patients with HP stratiﬁed by race/ethnicity.
A. Adegunsoye et al. / Respiratory Medicine 114 (2016) 53e6058literature. Similar to Sansores et al., we found that digital clubbing
was prevalent and predictedworse outcomes on univariate analysis
[20]. Mooney et al. studied predictors of transplant-free survival in
HP, and found that crackles, pulmonary function tests, and oxygen
therapy were associated with outcome on univariate analysis [15].
While we conﬁrmed a similar association between oxygen therapy
and transplant-free survival in our entire cohort, we additionally
found that a lower BMI was a poor prognostic marker. We also
found that FVC and DLCO, key physiologic parameters of the ILD-
GAP risk prediction model, were predictors of poor outcome.
Lastly, like Mooney et al., we found that the HRCT ﬁbrosis score
independently predicted worse prognosis in our entire HP cohort
[15].
To our knowledge, the role of race/ethnicity in predicting out-
comes has not been previously studied in HP. In multivariable
analysis, we found that Caucasian subjects were 9.33 times more
likely to die or undergo a lung transplant during follow-up than
non-Caucasian patients. These ﬁndings may support a genetic role
as has been suggested in prior studies by others, in theTable 6
Variables predicting survival in patients with HP.
Characteristic Unadjusted (n ¼ 120)
HR p-value
Autoimmune disease or features (HPAF) 1.28 0.591
Age 1.02 0.184
Gender 1.09 0.798
Caucasian race 8.42 0.036
BMI 0.95 0.034
Digital clubbing 3.47 <0.001
HRCT ﬁbrosis score 1.04 <0.001
FVC@ (% predicted) 0.94 <0.001
DLCO (% predicted) 0.96 <0.001
Oxygen therapy 4.38 0.001
HP¼Hypersensitivity Pneumonitis; HPAF¼Hypersensitivity Pneumonitis with Autoimm
a Adjusted for all variables listed above; @n ¼ 119.pathogenesis or disease course of HP but require validation [21,22].
This is the ﬁrst systematic study to examine the presence of
autoimmune diseases or speciﬁc CTD features in HP and their
impact on patient outcomes. As might be expected given the higher
prevalence of autoimmune diseases in women [23], our HPAF
cohort was predominantly female. Although digital clubbing is
commonly seen in HP [20], this was an uncommon ﬁnding in our
HPAF patients. After controlling for disease severity as measured by
pulmonary function tests and HRCT ﬁbrosis score, we found that
the presence of autoimmune disease or speciﬁc predeﬁned auto-
immune features remained a signiﬁcant risk factor for poor
outcomes.
The reasons underlying an association between autoimmunity
and HP are unclear. Alteration of the pulmonary epithelium by
inhaled environmental agents has been shown to promote post-
translational modiﬁcations, which eventually alter respiratory
mucosal proteins and results in the production of several citrulli-
nated self-proteins [24]. This pathophysiologic process may explain
the autoimmune phenomenon observed in our study in whichAdjusteda (n ¼ 118)
95% CI HR p-value 95% CI
0.53e3.10 4.45 0.010 1.43e13.88
0.99e1.06 1.00 0.893 0.95e1.05
0.55e2.17 1.73 0.151 0.82e3.65
1.15e61.68 9.33 0.037 1.14e76.30
0.90e0.99 0.95 0.076 0.89e1.01
1.77e6.81 1.34 0.469 0.60e2.99
1.02e1.05 1.02 0.045 1.00e1.04
0.92e0.97 0.97 0.059 0.94e1.00
0.95e0.98 0.99 0.489 0.97e1.01
1.81e10.59 2.51 0.094 0.85e7.38
une features as deﬁned in the text.
A. Adegunsoye et al. / Respiratory Medicine 114 (2016) 53e60 59almost half of those subjects with HP who did not meet our HPAF
criteria had either a positive ANA or CTD symptoms. Perhaps like
cigarette smokers [25,26] and coal workers who develop RA [27],
silica-exposed individuals who develop RA and SLE [28e31],
farmers at increased risk of primary systemic vasculitis [32] and the
World Trade Center ﬁreﬁghters/rescue workers who developed
diverse CTDs [33], inhaled environmental exposures may trigger
autoimmune processes in genetically susceptible individuals.
Our study has several limitations. First, this is a retrospective
study, although all data were prospectively acquired. Second, our
cohort is drawn from a single tertiary referral center with expertise
in ILD and these ﬁndings require external validation. Third, we
recognize that beyond those patients with autoimmune disease,
deﬁnitions of autoimmune features have varied in the literature
[2,7,8]. We chose previously published and frequently cited criteria
for autoimmune features that utilize more speciﬁc symptoms and
serologies.
4. Conclusion
Our ﬁndings show that HP may coexist with autoimmune dis-
ease or features in the same patient and manifest as advanced ILD
with increased mortality. Careful consideration should be given to
the coexistence of both processes especially in female patients.
Whether pre-existing autoimmunity delays recognition of HP and/
or contributes to a more exuberant inﬂammatory response de-
serves further study. It is currently unknown if chronic environ-
mental antigen exposure precipitates and/or exacerbates
autoimmune disease. Recognition of autoimmunity in patients with
HP may have an impact on subsequent ILD management and dis-
ease course.
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